Skip to content

How the Microbiota in the Lower Respiratory Tract Influences the Development and Exacerbation of Chronic Obstructive Pulmonary Disease

How the Microbiota in the Lower Respiratory Tract Influences the Development and Exacerbation of Chronic Obstructive Pulmonary Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019224
Enrollment
Unknown
Registered
2018-10-31
Start date
2018-12-10
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Case series:Nil

Sponsors

Zhongshan hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Comply with the Diagnostic Criteria of the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD-2018); 2. patients did not take antibiotics 1 month before enrollment, did not take antiviral drugs 1 week before enrollment; 3. Ability to communicate in language or text, agree to participate in the study and sign informed consent, and have the ability to complete trial-related inspections; 4. aged 18 to 80 years old.

Exclusion criteria

Exclusion criteria: 1. severe heart, liver, kidney disease: severe liver dysfunction (ALT or AST = 3 times normal); severe renal insufficiency (serum creatinine > 451µmol/L); chronic congestive heart failure (heart function NYHA III-IV grade ), affecting the progress of inspection results; 2. other respiratory diseases: clinical diagnosis of lung cancer, bronchiectasis, pneumoconiosis or other simple restrictive ventilatory dysfunction; active tuberculosis; pulmonary mycosis; patients who have undergone lung resection; 3. long-term use of systemic (oral or intravenous) hormone dose is unstable (ie dose stabilization time Less than 6 weeks) or a dose of hormone greater than 10 mg/d of prednisone, or long-term use of antibiotics; 4. immunodeficient patients, such as malignant tumors, organ or bone marrow transplant or AIDS or nearly 3 months to take immunosuppressive organs or bone marrow transplant patients; 5. have a history of chronic alcohol abuse, drug abuse, or any factors that affect compliance; 6. Patients who have participated in any interventional clinical study 63 months ago; 7. pregnant and lactating women; 8. Other reasons that the investigator believes are not suitable for this test.

Design outcomes

Primary

MeasureTime frame
lung tissue biopsy;

Secondary

MeasureTime frame
Blood routine;Blood gas analysis;CAT score;SGRQ score;mMRC score;Pulmonary function tests;Pulmonary function tests;Sputum cytology counting and classification;Sputum microbiological testing.;Inflammatory factor;Electrocardiogram;Echocardiography;Chest imaging examination;Arterial oxygen concentration;The total number of acute exacerbations in a year;Moderate and severe acute exacerbation within one year;

Countries

China

Contacts

Public ContactZhang Jing

Zhongshan Hospital, Fudan University

huxizhangjing@foxmail.com+86 13472782754

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026